HomeTriazolamTriazolam + Lumacaftor And Ivacaftor

Does Triazolam Interact with Lumacaftor And Ivacaftor?

Triazolam and Lumacaftor And Ivacaftor have a unknown drug interaction according to U.S. FDA drug labeling data. Co-administration of ORKAMBI is not recommended with sensitive CYP3A substrates or CYP3A substrates with a narrow therapeutic index [see Warnings and Precautions (5.8) and Clinical Pharmacology (12.3) ] such as: Benzodiazepines : midazolam, triazolam (consider an alternative to these benzodiazepines). Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.

Severity
Unknown
Triazolam Class
Benzodiazepine
Lumacaftor And Ivacaftor Class
Cystic Fibrosis Transmembrane Conductance Regulator Potentiator
Management
Consult your pharmacist
Data Source
U.S. FDA via OpenFDA

What To Tell Your Doctor or Pharmacist

If you are taking Triazolam and your doctor is considering prescribing Lumacaftor And Ivacaftor (or vice versa), make sure to:

  • Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
  • Ask whether the benefits of combining these medications outweigh the risks for your specific situation
  • Ask what symptoms to watch for that would indicate the interaction is causing problems
  • Never stop or change either medication without first consulting your healthcare provider
💊 Triazolam+💊 Lumacaftor And Ivacaftor(Orkambi)

Severity & Interaction Details

ℹ️
unknown
Interaction documented — severity unclassified
The FDA label notes an interaction but the severity is not classified in our dataset.
Severity scale
MinorContra
On record
Yes
Drug A class
Benzodiazepine
Drug B class
Cystic Fibrosis Transmembrane Conductance Regulator Potentiator
Source
FDA drug label - lumacaftor and ivacaftor

What this means in plain English

Co-administration of ORKAMBI is not recommended with sensitive CYP3A substrates or CYP3A substrates with a narrow therapeutic index [see Warnings and Precautions (5.8) and Clinical Pharmacology (12.3) ] such as: Benzodiazepines : midazolam, triazolam (consider an alternative to these benzodiazepines).

Share this result:XFacebookWhatsAppReddit
Add more drugs
Check Triazolam and Lumacaftor And Ivacaftor against your full medication list

Most patients take more than two medications. CDI checks every pair across up to 20 drugs simultaneously — including OTCs and common supplements.

Add more drugs →

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine. For informational purposes only. Always consult your pharmacist or physician.